BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 million, has announced the progression of its Phase 1 clinical trial with ...
Some results have been hidden because they may be inaccessible to you